SCHEMBL2196140

SCHEMBL2196140

CCC(=O)c1cc2c(cc1O)C(C)(C)CCC2(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 13/20 0.55
RARB P10826 5/20 0.52
HMGCR P04035 1/20 0.49
HSP90AB1 P08238 1/20 0.47
RARA P10276 5/20 0.47
RARG P13631 5/20 0.47
HNF4A P41235 2/20 0.43
RXRB P28702 3/20 0.42
RXRG P48443 3/20 0.42
CA9 Q16790 1/20 0.41
RECQL P46063 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.40
CYP26A1 O43174 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15849979 0.84 RXRA (0.50) RXRARARBRARARARGHNF4A
SCHEMBL7149480 0.80 RXRA (0.69) RXRARARBRARARARGRXRB
SCHEMBL726366 0.80 RXRA (0.59) RXRARARBRARARARGRXRB
SCHEMBL30701833 0.80 RXRA (0.69) RXRARARBRARARARGRXRB
SCHEMBL5861140 0.79 RXRA (0.63) RXRARARBRARARARGHNF4A
SCHEMBL6834543 0.79 RXRA (0.58) RXRARARBHMGCRRARARARG
SCHEMBL5859918 0.76 RXRA (0.59) RXRARARBRARARARGHNF4A
SCHEMBL2191766 0.76 RXRA (0.55) RXRARARBRARARARGRXRB
SCHEMBL2196986 0.76 RXRA (0.55) RXRARARBRARARARGRXRB
SCHEMBL6838361 0.75 RXRA (0.49) RXRARARBRARARARGHNF4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765719-B2 Therapeutic drug for adult T-cell leukemia KAGOSHIMA UNIVERSITY (JP) 2014-07-01 US disclosed
US-8765719-B2 Therapeutic drug for adult T-cell leukemia KAGOSHIMA UNIVERSITY (JP) 2014-07-01 US disclosed
US-8765719-B2 Therapeutic drug for adult T-cell leukemia KAGOSHIMA UNIVERSITY (JP) 2014-07-01 US disclosed
EP-2345409-A1 THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA Kagoshima University (JP) 2011-07-20 EP disclosed
US-20110172185-A1 THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA KAGOSHIMA UNIVERSITY (JP) 2011-07-14 US disclosed
US-6759547-B1 REDUCES SERUM GLUCOSE AND SERUM TRIGLYCERIDE LEVELS IN DIABETIC MAMMALS WITHOUT THE UNDESIRABLE PROPERTIES OF REDUCING SERUM THYROXINE LEVELS AND TRANSIENTLY RAISING TRIGLYCERIDE LEVELS ALLERGAN, INC. 2004-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172185-A1 THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA CBR3, CD47, ATL3 RXRA 1135/4885RARB 2945/4885HMGCR 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.